SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

APOBEC Mutagenesis: a novel Achilles heel of Breast cancer

The AMBER project aims to unravel APOBEC mutagenesis in breast cancer to identify prevention and treatment strategies, potentially transforming it into a targetable vulnerability.

Subsidie
€ 2.499.990
2022

Projectdetails

Introduction

APOBEC mutagenesis is a cellular mechanism by which genetic alterations are acquired somatically, driven by APOBEC enzyme family members. This mechanism is prominently observed in 15% of primary and 25% of recurrent breast cancer, the most common cause of cancer-related death in middle-aged women. Current evidence suggests APOBEC mutagenesis contributes to all disease stages, i.e., cancer initiation, progression, and treatment resistance.

Project Overview

The core idea of the AMBER project is that unraveling the mechanism of APOBEC mutagenesis induction and maintenance will turn this mechanism into breast cancer’s Achilles heel. To prove this, I will answer several challenging research questions:

  1. Why is APOBEC mutagenesis operational in breast cancer?
  2. How does APOBEC contribute to disease progression?
  3. Can we target APOBEC mutagenesis or APOBEC-driven tumors specifically?

Research Objectives

Epidemiological and Molecular Evidence

First, I will reveal epidemiological and molecular evidence for factors inducing APOBEC mutagenesis in breast cancer. This may help to prevent APOBEC mutagenesis from occurring, potentially decreasing breast cancer incidence.

Link to Disease Progression

Second, using global and single-cell genomics, I will secure a link between APOBEC mutagenesis and disease progression, giving leads to delay progression.

Targeting Vulnerabilities

Third, I will exploit a potential vulnerability of APOBEC-driven breast cancer, since I have found that these tumors may depend on a proficient homologous DNA repair (HR) pathway. When experimentally confirmed, targeting HR may extinguish APOBEC-driven disease.

Immune Response and Neo-epitopes

Finally, I have observed that APOBEC mutagenesis associates with a profound immune response. I hypothesize that this is due to a new type of neo-epitopes being produced. If proven true, targeting these neo-epitopes provides another effective means to eradicate APOBEC-driven tumors.

Conclusion

I am confident AMBER will provide the fundamental insights into APOBEC mutagenesis needed to turn it into an Achilles heel which may help to prevent, delay, or cure APOBEC-driven breast cancer.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.499.990
Totale projectbegroting€ 2.499.990

Tijdlijn

Startdatum1-10-2022
Einddatum30-9-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMpenvoerder

Land(en)

Netherlands

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancer

The ADRIP study aims to investigate the role of APOBEC3A in driving drug resistance and intra-tumoral heterogeneity in pancreatic cancer, with potential therapeutic implications.

ERC Starting...€ 1.880.615
2025
Details

Probing the malignant potential of mutant clones in healthy mammary tissue by successive mutagenesis

SUCCESSion aims to develop a novel gene editing technology to study the impact of mutation order on pre-cancer evolution and environment rewiring, enhancing understanding and early intervention strategies for cancer.

ERC Starting...€ 1.497.740
2024
Details

Organ and mutation dependencies shaping the tumor microenvironment

This project aims to analyze the tumor microenvironments of BRCA-driven cancers across four organs to identify common design principles for developing targeted therapies.

ERC Consolid...€ 2.000.000
2022
Details

Targeting SWI/SNF-related chromatin remodelling defects in solid tumours

This project aims to uncover and exploit synthetic lethal vulnerabilities in SWI/SNF-deficient tumours to enhance anti-tumour immune responses and develop novel immuno-oncology therapies.

ERC Starting...€ 1.499.887
2023
Details

Targeting the Polycomb Machinery in BAP1-related Pathologies

The T-BAP project aims to develop targeted compounds against PRC1.3/5 to restore normal H2Aub1 levels and create therapeutic strategies for cancers linked to BAP1 mutations.

ERC Proof of...€ 150.000
2024
Details
ERC Starting...

Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancer

The ADRIP study aims to investigate the role of APOBEC3A in driving drug resistance and intra-tumoral heterogeneity in pancreatic cancer, with potential therapeutic implications.

ERC Starting Grant
€ 1.880.615
2025
Details
ERC Starting...

Probing the malignant potential of mutant clones in healthy mammary tissue by successive mutagenesis

SUCCESSion aims to develop a novel gene editing technology to study the impact of mutation order on pre-cancer evolution and environment rewiring, enhancing understanding and early intervention strategies for cancer.

ERC Starting Grant
€ 1.497.740
2024
Details
ERC Consolid...

Organ and mutation dependencies shaping the tumor microenvironment

This project aims to analyze the tumor microenvironments of BRCA-driven cancers across four organs to identify common design principles for developing targeted therapies.

ERC Consolidator Grant
€ 2.000.000
2022
Details
ERC Starting...

Targeting SWI/SNF-related chromatin remodelling defects in solid tumours

This project aims to uncover and exploit synthetic lethal vulnerabilities in SWI/SNF-deficient tumours to enhance anti-tumour immune responses and develop novel immuno-oncology therapies.

ERC Starting Grant
€ 1.499.887
2023
Details
ERC Proof of...

Targeting the Polycomb Machinery in BAP1-related Pathologies

The T-BAP project aims to develop targeted compounds against PRC1.3/5 to restore normal H2Aub1 levels and create therapeutic strategies for cancers linked to BAP1 mutations.

ERC Proof of Concept
€ 150.000
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.